AnaptysBio initiated with an Outperform at Wolfe Research
Wolfe Research analyst Andy Chen initiated coverage of AnaptysBio (ANAB) with an Outperform rating and $25 price target The stock’s current ...
AnaptysBio, Vanda announce exclusive global license agreement for Vanda
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Contract Pharma14h
Vanda & AnaptysBio Partner for the Development and Commercialization of Imsidolimab
Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, ...
Vanda, Anaptys Join on Development Pact
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and AnaptysBio, Inc. (Anaptys) (NASDAQ: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab ...
The Lancet5h
Applying the estimand framework to inflammatory bowel disease clinical trials
Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets ...
Le Lézard16h
Canon Breaks Visual Boundaries with 'World Unseen' at Sikka Art & Design Festival
Immersive exhibition reimagines art through multi-sensory experience to improve the accessibility of visual arts for those with visual impairments.Blending technology, innovation, and creativity, ...